Compare Honeywell Aerospace Inc. Common Stock (HONA) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Honeywell Aerospace Inc. Common Stock vs Johnson & Johnson — how do they compare? Honeywell Aerospace Inc. Common Stock trades at $157.74 (market cap $49.68B), while Johnson & Johnson trades at $257 (market cap $611.90B). The key difference: Johnson & Johnson is far larger — about 12.3× Honeywell Aerospace Inc. Common Stock's market cap, and Johnson & Johnson pays a 2.11% dividend while Honeywell Aerospace Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Honeywell Aerospace Inc. Common Stock for 0 Days and Johnson & Johnson for 129 Days on average.
| HONA | JNJ | |
|---|---|---|
Market Cap | $49.68B | $611.90B |
Volume | 2,156,288 | 9,651,904 |
Sector | Industrials | Health |
52-Week High | $269.95 | $278.43 |
52-Week Low | $151.58 | $186.00 |
Typical Hold Time | 0 Days | 129 Days |
Enterprise Value | $64.51B | $640.18B |
Dividend Yield | — | 2.11% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HONA trades at $158.18, up 0.58% today, with neutral technical indicators showing support at $156 and resistance at $160. The company reported Q2 2026 EPS of $1.87, missing expectations of $2.07, while revenue grew to $17.40B in 2025. Analyst consensus remains mixed with a $211.25 price target, but multiple class action lawsuits filed in October 2026 create significant legal overhang.
HONA faces near-term headwinds from earnings miss and legal challenges, though strong cash flow generation and analyst price targets suggest long-term potential. Investors should weigh the 42.9% buy rating against litigation risks and declining profit margins projected for 2026.
Johnson & Johnson (JNJ) trades at $248.61, down 5.73% in the last session, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q3 2026 earnings, beating estimates with $2.59 EPS versus $2.52 expected, continuing a trend of three consecutive quarterly beats. JNJ maintains robust profitability with 67.91% gross margins and 21.48% net income margins, supported by $94.19B in 2025 revenue and $26.80B net income.
Analyst consensus remains positive with 52.5% buy ratings and a $282.53 price target, representing 13.6% upside potential. Key risks include patent cliffs affecting pharmaceutical revenue and increasing debt-to-asset ratio reaching 24.06% in 2025. The company's diversified healthcare portfolio and strong dividend history provide stability, while new drug launches like Icotyde offer growth catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Honeywell Aerospace Inc. Common Stock
Honeywell Aerospace Inc. is an aerospace and defense technology company, spun off from Honeywell in June 2026, that designs and supplies avionics, propulsion components (including auxiliary power units and engines), and connectivity systems for commercial, defense, and space aircraft.
Read more on HONA →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
